Ambrx
Latest round
- Series E
Last raised
- Aug 2016
Total raised
- $122M
Investors
- 21
About Ambrx
Based in California, US, founded in 2003, Ambrx, Inc. develops engineered precision biologics to treat a broad range of diseases and disorders. Feng Tian is the current CEO of the company. In November 2020, Ambrx, Inc. The company has 70 employees as of June 2021. In June 2021, Ambrx, Inc. It trades on NYSE under the ticker symbol AMAM. Ambrx is developing a new class of engineered precision biologics (EPBs) that allow synthetic amino acids (SAAs) to be incorporated into proteins within live cells. Among the products in its pipeline are ARX788, ARX517, and ARX305. ARX788 is an anti-HER2 ADC currently being studied broadly in breast cancer, gastric/GEJ cancer, and other solid tumor clinical trials. ARX517 targets the prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. ARX305 targets CD70 on cancer cells. CD70 is overexpressed in a broad range of solid and hematologic tumors such as renal cell carcinoma (RCC), nasopharyngeal cancers, multiple myeloma, non-Hodgkin’s lymphoma, and acute myeloid leukemia (AML). The company's total revenue in 2020 was USD 13,671 which was an increase from that of 2019. In 2019 the total revenue generated was USD 10,311.
Who invested in Ambrx
21 investors across 6 rounds
See all investors in Ambrx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ambrx
Who invested in Ambrx?
Ambrx has 21 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ambrx raised?
Ambrx has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Ambrx last raise money?
Ambrx's most recent round on record is a Series E, in Aug 2016.
What does Ambrx do?
Based in California, US, founded in 2003, Ambrx, Inc.
Where is Ambrx headquartered?
Ambrx is headquartered in US.
Which VCs invest in companies like Ambrx?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ambrx's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Ambrx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.